Mode
Text Size
Log in / Sign up
N/A N=53 Treatment

The Neuro Zti Cochlear Implant System Efficacy and Safety in Adults

Hearing Loss, Sensorineural · Hearing Loss, Cochlear · Deafness

Enrolled (actual)
53
Serious AEs
5.9%
Results posted
Nov 2021
Primary outcome: Primary: Change in Hearing In Noise Test Score in Quiet (HINT-Q) From Baseline to 6 Months in English-speaking Participants. — 51.5 percent change words correctly repeated

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Neuro Zti (Device); Neuro One (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Oticon Medical
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Hearing In Noise Test Score in Quiet (HINT-Q) From Baseline to 6 Months in English-speaking Participants.
51.5
PRIMARY
Major Related Adverse Event (AE)
1; 1; 2
SECONDARY
Clinical Benefit on English-speaking Participants
26; 29; 30; 2; 3; 2
SECONDARY
Hearing In Noise Test Score in Quiet (HINT-Q) Pre-operatively, at 3-, 6- and 12-Months on English-speaking Participants
13.3; 55.8; 64.8; 70.1
SECONDARY
Hearing In Noise Test Score in Noise (HINT-N) Pre-operatively, at 3-, 6- and 12-Months on English-speaking Participants
13.3; 43.8; 52.3; 57.6
SECONDARY
Minor Adverse Events (AE)
16; 20; 31

Summary

The purpose of the study is to assess the efficacy and the safety profile of the Neuro Cochlear Implant System (CIS) in adults with severe-to-profound hearing loss.

Eligibility Criteria

Inclusion criteria

  • Adults, eighteen (18) years of age or older.
  • Bilateral severe-to-profound sensorineural hearing loss, defined by pure-tone average (PTA) ≥70 dB HL (Hearing Level) at 500, 1000 and 2000 Hz on both ears.
  • HINT sentences recognition scores in quiet ≤ 50% correct, in the best-aided listening condition.
  • Post-lingual onset of deafness.
  • Primary implantation (no re-implantation).
  • Up-to-date pneumococcal vaccine.

Exclusion criteria

  • Medical conditions that contraindicate undergoing cochlear implant surgery (middle ear diseases i.e. AOM/CSOM (Acute Otitis Media/Chronic Suppurative Otitis Media) , lesions of auditory nerve, pathologies of central auditory pathway, otosclerosis; cochlear malformation i.e. Mondini malformation, cochlear ossification, large vestibular aqueduct).
  • Unrealistic expectations regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure and medical device.
  • Unwillingness or inability of the candidate to comply with all investigational requirements.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02941627). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search